title: [Suppressive effect in vitro of resveratrol on ADP induced human platelet aggregation and its active mechanism].
abstract: Resveratrol (RESV) is a polyphenolic compound existed in native plants such as grape, fleeceflower root, and peanut, etc. The aim of this study was to investigate the effects in vitro of RESV on adenosine diphosphate (ADP)-induced platelet aggregation, platelet membrane-bound fibrinogen (PFig) its mechanism of action. The effects of RESV and phospholipase Cbeta inhibitor (U73122) on ADP-induced healthy human volunteers platelet aggregation, PFig, and the expression of phospho-phospholipase Cbeta3 (P-PLCbeta3) and total-phospholipase Cbeta3 (T-PLCbeta3) were studied with platelet aggregometer, flow cytometry and Western blotting, respectively. Compared with control group, RESV at 25, 50 and 100 micromol x L(-1) inhibited ADP-induced platelet aggregation and PFig in a dose dependent manner, and RESV at 25 micromol x L(-1) obviously reduced expression of P-PLCbeta3 and ratio of P-PLCbeta3 to T-PLCbeta3 in platelet of healthy human volunteers. Furthermore, RESV and U73122 had additive effect in inhibiting platelet aggregation and PFig. All these suggested that RESV inhibited platelet aggregation and PFig induced by ADP partly through decreasing the activity of PLCbeta of platelets, and that RESV had definite effect of antiplatelet and might be developed as a novel antithrombotic agent.
authors.affiliation: First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou 310003, China.
authors.forename: Yu-Min
authors.initials: YM
authors.lastname: Yang
authors.forename: Xin-Xiang
authors.initials: XX
authors.lastname: Wang
authors.forename: Shi-Jun
authors.initials: SJ
authors.lastname: Wang
authors.forename: Hong-Qiang
authors.initials: HQ
authors.lastname: Wang
authors.forename: Jun-Zhu
authors.initials: JZ
authors.lastname: Chen
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004963:Estrenes / Q000494:pharmacology; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D054799:Phospholipase C beta / Q000378:metabolism*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011760:Pyrrolidinones / Q000494:pharmacology; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D004963:Estrenes; D010975:Platelet Aggregation Inhibitors; D011760:Pyrrolidinones; D013267:Stilbenes; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D000244:Adenosine Diphosphate; D005340:Fibrinogen; D054799:Phospholipase C beta; D000077185:Resveratrol